"Just caring": Can we afford the ethical and economic costs of circumventing cancer drug resistance?

Journal of Personalized Medicine

Volumn 3, Issue 3, 2013, Pages 124-143

  Fleck, Leonard M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cancer; Health care justice; Health care rationing; Just caring problem; Oncology; Personalized medicine; Rational democratic deliberation; Targeted therapies

Indexed keywords

BEVACIZUMAB; DASATINIB; DAUNORUBICIN; IMATINIB; LAPATINIB; LETROZOLE; NILOTINIB; PACLITAXEL;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMIC ASPECT; ETHICS; GASTROINTESTINAL TUMOR; GENE MUTATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; LIFE EXPECTANCY; MOLECULARLY TARGETED THERAPY; NEOPLASM; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

EID: 84911872464     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm3030124     Document Type: Article

References (56)

1. Lemonick, M.D.; Park, A. New hope for cancer. TIME 2001. Available online: http://www.time.com/time/magazine/article/0,9171,999978,00.html (accessed on 30 April 2013).
2. Fleck, L.M. Just Caring: Health Care Rationing and Democratic Deliberation; Oxford University Press: New York, NY, USA, 2009.
3. Garraway, L.A.; Jaenne, P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012, 2, 214-226.
4. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30, 679-692.
5. Nagaprashantha, L.; Vartak, N.; Awasthi, S.; Awasthi, S.; Singhal, S.S. Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors. Pharm. Res. 2012, 29, 621-636.
6. Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buocarino, M.; Siravegna, G.; et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486, 532-536.
7. Gonalez, D.; Clarke, P.A.; Al-Lazikani, B.; workman, P. Personalized cancer medicine: Molecular diagnostics, predictive biomarkers, and drug resistance. Clin. Pharmacol. Ther. 2013, 93, 252-259.
8. Fidler, I.J.; Hart, I.R. Biological diversity in metastatic neoplasms: Origins and implications. Science 1982, 217, 998-1003.
9. Heppner, G.H. Tumor heterogeneity. Cancer Res. 1984, 44, 2259-2265.
10. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Tarpey, P.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883-892.
11. Raspe, E.; Decraene, C.; Berx, G. Gene expression profiling to dissect the complexity of cancer biology: Pitfalls and promise. Semin. Cancer Biol. 2012, 22, 250-260.
12. Longo, D.L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 2012, 366, 956-957.
13. Yap, T.A.; Omlin, A.; de Bono, J.S. Development of therapeutic combinations targeting major cancer signaling pathways. J. Clin. Oncol. 2013, 31, 1592-1605.
14. Lee, J.H.; Kim, D.G.; Bae, T.J.; Rho, K.; Kim, J.T.; Lee, J.J.; Jang, Y.; Kim, B.C.; Park, K.M.; Kim, S.; et al. CDA: Combinatorial drug discovery using transcriptional response modules. PLoS One 2012, 7, e42573.
15. Castano, Z.; Fillmore, C.M.; Kim, C.F.; McAllister, S.S. The bed and the bugs: Interactions between the tumor microenvironment and cancer stem cells. Semin. Cancer Biol. 2012, 22, 462-470.
16. Prasasya, S.D.; Tian, D.; Kreeger, P.K. Analysis of cancer signaling networks by systems biology to develop therapies. Semin. Cancer Biol. 2011, 21, 200-206.
17. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, doi:10.1056/NEJMoa1301689
18. Steensma, D.P. The beginning of the end of the beginning in cancer genomics. N. Engl. J. Med. 2013, doi:10.1056/NEJMe1303816
19. Gatenby, R.A. A change of strategy in the war on cancer. Nature 2009, 459, 508-509.
20. Keehan, S.P.; Sisko, A.M.; Truffer, C.J.; Poisal, J.A.; Cuckler, G.A.; Madison, A.J.; Lisovitz, J.M.; Smith, S.D. National health spending projections through 2020: Economic recovery and reform drive faster spending growth. Health Aff. 2011, 30, 1594-1605.
21. Callahan, D. What Kind of Life: The Limits of Medical Progress; Simon & Schuster: New York, NY, USA, 1990; Chapter 2.
22. American Heart Association Statistics Committee. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012, 125, e2-e220
23. Siegal, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
24. Wildavsky, A. Doing better and feeling worse: The political pathology of health policy. Daedalus 1977, 106, 105-123.
25. Fojo, T.; Parkinson, D.R. Biologically targeted cancer therapy and marginal benefits: Are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 2010, 16, 5972-5980.
26. MacReady, N. The climbing costs of cancer care. J. Natl. Cancer Inst. 2011, 103, 1433-1435.
27. Elkin, E.B.; Bach, P.B. Cancer's next frontier: Addressing high and increasing costs. JAMA 2010, 303, 1086-1087.
28. Cohen, J.; Looney, W. What is the value of oncology medicines? Nat. Biotechnol. 2010, 28, 1160-1163.
29. Fojo, T.; Grady, C. How much is life worth: Non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 2009, 101, 1044-1048.
30. Fleck, L.M. Last chance therapies: Can a just and caring society do health care rationing when life itself is at stake? Yale J. Health Policy Law Ethics 2002, 2, 255-298.
31. Daniels, N.; Sabin, J.E. Last chance therapies and managed care: Pluralism, fair procedures, and legitimacy. Hastings Cent. Rep. 1998, 28, 27-41.
32. Calabresi, G.; Bobbitt, P. Tragic Choices; W.W. Norton and Company: New York, NY, USA, 1978.
33. Bock, C.; Lengauer, T. Managing drug resistance in cancer: Lessons from HIV therapy. Nat. Rev. Cancer 2012, 12, 494-501.
34. Ubel, P. Why It's Time for Health Care Rationing; MIT Press: Cambridge, MA, USA, 2000.
35. Callahan, D. False Hopes: Why America's Quest for Perfect Health is a Recipe for Failure; Simon & Schuster: New York, NY, USA, 1998.
36. Daniels, N. Just Health: Meeting Health Needs Fairly; Cambridge University Press: New York, NY, USA, 2008.
37. Newdick, C. Who Should We Treat? Rights, Rationing, and Resources in the NHS, 2nd ed.; Oxford University Press: Oxford, UK, 2005.
38. Engelhardt, H.T. The Foundations of Bioethics, 2nd ed.; Oxford University Press: New York, NY, USA, 1996.
39. Institute of Medicine. America's Uninsured Crisis: Consequences for Health and Health Care; The National Academies Press: Washington, D.C., USA, 2009.
40. Eddy, D.M. Clinical Decision Making: From Theory to Practice; Jones and Bartlett: Boston, MA, USA, 1996.
41. Veatch, R.M. The Foundations of Justice: Why the Retarded and the Rest of Us Have Claims to Equality; Oxford University Press: New York, NY, USA, 1986.
42. Harris, J. The Value of Life; Routledge & Kegan Paul: London, UK, 1985.
43. Dworkin, R. Sovereign Virtue: The Theory and Practice of Equality; Harvard University Press: Cambridge, MA, USA, 2000.
44. Christiano, T. The Constitution of Equality: Democratic Authority and Its Limits; Oxford University Press: New York, NY, USA, 2008.
45. Rawls, J. A Theory of Justice; Harvard University Press: Cambridge, MA, USA, 1971.
46. Konski, A. The war on cancer: Progress at what price? J. Clin. Oncol. 2011, 29, 1503-1504.
47. Sulmasy, D.P. Cancer care, money, and the value of life: Whose justice? Which rationality? J. Clin. Oncol. 2007, 25, 217-222.
48. Theriault, R.L. Health care costs: How do we decide value? When do we decide? How do we particularize the decisions? Oncologist 2012, 17, 157-159.
49. National Institute of Clinical Excellence. Available online: http://www.nice.org.uk/ (accessed on 7 May 2013).
50. Schneider, B.P.; Wang, M.; Radovich, M.; Sledge, G.W.; Badva, S.; Thor, A.; Flockhart, D.A.; Hancock, B.; Davidson, N.; Gralow, J.; et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer ECOG 2100. J. Clin. Oncol. 2008, 26, 4672-4678.
51. Sawyers, C.L. The cancer biomarker problem. Nature 2008, 452, 548-552.
52. Johnston, F.; Pippen, J.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, V.L.; Romieu, G.; Manikhas, A.; Kennedy, M.J.; et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, 5538-5546.
53. Malvezzi, M.; Bertuccio, P.; Levi, F.; La Vecchia, C.; Negri, E. European cancer mortality predictions for the year 2013. Ann. Oncol. 2013, 24, 792-800.
54. Mariotto, A.B.; Yabroff, K.R.; Shao, Y.; Feuer, E.J.; Brown, M.L. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl. Cancer Inst. 2011, 103, 117-128.
55. New 50 million cancer fund already intellectually bankrupt. Lancet 2010, 376, 389.
56. Habermas, J. Between Facts and Norms: Contributions to a Discourse Theory of Law and Democracy, translated by William Rehg; MIT Press: Cambridge, MA, USA, 1996.